Industry
Biotechnology
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Loading...
Open
8.59
Mkt cap
107M
Volume
270K
High
8.70
P/E Ratio
-1.80
52-wk high
22.49
Low
8.00
Div yield
N/A
52-wk low
4.53
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:40 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 10:35 am
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 12:00 pm
Portfolio Pulse from Avi Kapoor
July 05, 2024 | 4:59 pm
Portfolio Pulse from Benzinga Insights
July 05, 2024 | 2:59 pm
Portfolio Pulse from Nabaparna Bhattacharya
July 03, 2024 | 11:12 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.